Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Treasury Shares (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 7 years of Treasury Shares data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 100.72% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 100.72%, while the annual FY2025 figure was $2.6 million, 100.72% up from the prior year.
  • Treasury Shares reached $2.6 million in Q4 2025 per SNDX's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.6 million in Q4 2025 and bottomed at $132333.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $634897.7, with a median of $392288.0 recorded in 2023.
  • Peak YoY movement for Treasury Shares: skyrocketed 615.31% in 2021, then soared 52.89% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $132333.0 in 2021, then surged by 69.87% to $224788.0 in 2022, then skyrocketed by 131.08% to $519436.0 in 2023, then soared by 151.06% to $1.3 million in 2024, then soared by 100.72% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.6 million in Q4 2025, $1.3 million in Q4 2024, and $519436.0 in Q4 2023.